【レポートの概要（一部）】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Disease overview
• Understanding RA
• Etiology and pathophysiology
• Signs and symptoms
• Diagnosis
• Disease management
• Economic burden of RA
• Epidemiology
PART 06: Impact of biologics in RA
PART 07: Pipeline portfolio
• Novel mechanisms targeted by pipeline candidates
• Clinical trials for RA
PART 08: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 09: Market segmentation by drug class
• DMARDs
• NSAIDs
• Corticosteroids
• Analgesics
• Others
• Global DMARDs market
• Global NSAIDs market
• Global corticosteroids market
• Global analgesics market
PART 10: Market segmentation by MOA
• TNF inhibitors
• IL-1 blockers
• JAK inhibitors
• Selective costimulation modulators
PART 11: Market segmentation by type of molecule
• Biologics
• Small molecules
PART 12: Market segmentation by ROA
• Oral
• Parenteral
• Topical
PART 13: Market segmentation by dosage form
• Solid
• Liquid
• Semi-solid
PART 14: Geographical segmentation
• RA drugs market in Americas
• RA drugs market in US
• RA drugs market in EMEA
• RA drugs market in Germany
• RA drugs market in UK
• RA drugs market in Spain
• RA drugs market in Italy
• RA drugs market in France
• Rheumatoid arthritis drugs market in APAC
• RA drugs market in Japan
• RA drugs market in Australia
• RA drugs market in India
• RA drugs market in China
PART 15: Key leading countries
PART 16: Market drivers
• Growing older population
• Market dominance of biologics
• Promising drug pipeline
• Changing lifestyle patterns
• Advances in diagnosis technology
PART 17: Impact of drivers
PART 18: Market challenges
• Increasing costs of biologicals
• Loss of patent exclusivity of branded therapies
• Use of complementary and alternative medicines (CAMs)
• Adverse effects of drugs
• Stringent regulations
PART 19: Impact of drivers and challenges
PART 20: Market trends
• Emergence of biosimilars
• Patient assistance programs
• Popularity of off-label and traditional treatment options
• Strategic alliances
• Increase in public awareness
PART 21: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• AbbVie
• Amgen
• BMS
• F. Hoffmann-La Roche
• Johnson & Johnson
• Pfizer
• Other prominent vendors
PART 22: Appendix4
• List of abbreviations4
PART 23: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for RA drugs
Exhibit 03: Classification of RA based on disease severity
Exhibit 04: Classification of RA based on disease severity 2016
Exhibit 05: Etiology and pathophysiology of RA
Exhibit 06: Signs and symptoms of RA
Exhibit 07: Diagnostic tests for RA
Exhibit 08: Treatment options for RA
Exhibit 09: Non-pharmacological therapies used for RA
Exhibit 10: Pharmacotherapy therapy for RA
Exhibit 11: Drugs used to treat RA
Exhibit 12: Classification of surgical treatment for RA
Exhibit 13: Percentage share of treatment of RA 2016
Exhibit 14: Historical milestones in treatment of RA
Exhibit 15: Treatment algorithm for RA
Exhibit 16: Economic burden of RA
Exhibit 17: Annual treatment costs of RA within Europe and US 2015 ($)
Exhibit 18: Cost difference between biological DMARDs and non-biological DMARDs
Exhibit 19: Projected prevalence of RA in Americas 2010-2030 ($ millions)
Exhibit 20: New cases of RA in UK per year 2016
Exhibit 21: Existing cases of RA in UK
Exhibit 22: Impact of biologics on various sectors
Exhibit 23: Pipeline molecules for RA
Exhibit 24: Novel targets of pipeline candidates
Exhibit 25: Candidates under development: Baricitinib
Exhibit 26: Candidates under development: Decernotinib
Exhibit 27: Candidates under development: CCX354
Exhibit 28: Candidates under development: Sirukumab
Exhibit 29: Candidates under development: Infliximab biosimilar
Exhibit 30: Candidates under development: Secukinumab
Exhibit 31: Candidates under development: Bimekizumab
Exhibit 32: Clinical trials of RA drugs by phase 2016
Exhibit 33: Clinical trials of RA drugs by status 2016
Exhibit 34: Global RA drugs market 2015-2020 ($ billions)
Exhibit 35: Opportunities in RA drugs industry
Exhibit 36: Five forces analysis
Exhibit 37: Global RA drugs market segmentation by drug class
Exhibit 38: Examples of non-biologic DMARDs and biologic DMARDs for RA
Exhibit 39: NSAIDs used to treat RA
Exhibit 40: Market share of global RA drugs market by drug class 2015
Exhibit 41: Global DMARDs market 2015-2020 ($ billions)
Exhibit 42: Global NSAIDs market 2015-2020 ($ billions)
Exhibit 43: Global corticosteroids market 2015-2020 ($ billions)
Exhibit 44: Global analgesics market 2015-2020 ($ billions)
Exhibit 45: Market segmentation of global RA drugs market by MOA
Exhibit 46: Mean percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 47: Global RA drugs market share by MOA 2015
Exhibit 48: Global RA drugs market segmentation by type of molecule
Exhibit 49: Global RA drugs market share by type of molecules 2015
Exhibit 50: Global RA drugs market segmentation by ROA
Exhibit 51: Global RA drugs market segmentation by ROA 2015
Exhibit 52: Global RA drugs market segmentation by dosage form
Exhibit 53: Global RA drugs market segmentation by dosage form 2015
Exhibit 54: Global RA drugs by geography 2015
Exhibit 55: Global RA drugs market by geography 2015-2020 ($ billions)
Exhibit 56: Global RA drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 57: RA drugs market in Americas 2015-2020 ($ billions)
Exhibit 58: RA drugs market in Americas by country 2015
Exhibit 59: RA drugs market in US 2015-2020 ($ billions)
Exhibit 60: RA drugs sales in US by drug class 2015
Exhibit 61: Drivers and challenges of RA drugs market in US
Exhibit 62: RA drugs market in EMEA 2015-2020 ($ billions)
Exhibit 63: RA drugs market in EMEA by country 2015
Exhibit 64: RA sales in EMEA by drug class 2015
Exhibit 65: RA drugs market in Germany 2015-2020 ($ billions)
Exhibit 66: RA drugs market in UK 2015-2020 ($ billions)
Exhibit 67: RA drugs market in Spain 2015-2020 ($ millions)
Exhibit 68: RA drugs market in Italy 2015-2020 ($ millions)
Exhibit 69: RA drugs market in France 2015-2020 ($ millions)
Exhibit 70: RA drugs market in APAC 2015-2020 ($ billions)
Exhibit 71: RA drugs market in APAC by country 2015
Exhibit 72: RA drugs market in Japan 2015-2020 ($ billions)
Exhibit 73: RA drugs sales in Japan by drug class 2015
Exhibit 74: Drivers and challenges to growth of RA drugs market in Japan
Exhibit 75: RA drugs market in Australia 2015-2020 ($ millions)
Exhibit 76: RA drugs sales in Australia by drug class 2015
Exhibit 77: Drivers and challenges in RA drugs market in Australia
Exhibit 78: RA drugs market in India 2015-2020 ($ billions)
Exhibit 79: RA sales in India by drug class 2015
Exhibit 80: RA drugs market in China 2015-2020 ($ millions)
Exhibit 81: RA drugs sales in China by drug class 2015
Exhibit 82: Key leading countries
Exhibit 83: Population aged 60 years and over: World, developed and developing regions ($ millions)
Exhibit 84: FDA approval of biologicals
Exhibit 85: List of pipeline molecules
Exhibit 86: Lifestyle factors – Risk of rheumatoid arthritis
Exhibit 87: Impact of drivers
Exhibit 88: Average annual treatment cost of Humira, Enbrel, and Remicade 2014 ($)
Exhibit 89: Approval and patent expiries of top selling biologics
Exhibit 90: CAM therapies for RA
Exhibit 91: Usage of CAM in US
Exhibit 92: Side effects associated with RA
Exhibit 93: Impact of drivers and challenges
Exhibit 94: Patient assistance programs offered by companies
Exhibit 95: Revenue share of RA drugs by vendors 2015
Exhibit 96: YoY sales comparison of top drugs 2012-2014 ($ billions)
Exhibit 97: Competitive assessment of top RA drugs
Exhibit 98: Revenue share of RA drugs 2015
Exhibit 99: AbbVie: Product segmentation by revenue 2014
Exhibit 100: AbbVie: YoY revenue and growth rate of Humira 2012-2014 ($ billions)
Exhibit 101: AbbVie: YoY revenue and growth rate of Humira (in US) 2012-2014 ($ billions)
Exhibit 102: AbbVie: YoY revenue and growth rate of Humira (ROW) 2012-2014 ($ billions)
Exhibit 103: Sales of Humira in major markets
Exhibit 104: AbbVie: SWOT analysis
Exhibit 105: Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2012-2014 ($ billions)
Exhibit 106: Amgen: YoY revenue and growth rate of Enbrel (in US) 2012-2014 ($ billions)
Exhibit 107: Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2012-2014 ($ millions)
Exhibit 108: Amgen: SWOT analysis
Exhibit 109: BMS: Segmentation by revenue 20141
Exhibit 110: BMS: YoY revenue and growth rate of Orencia 2012-2014 ($ billions)
Exhibit 111: BMS: YoY revenue and growth rate of Orencia (in US) 2012-2014 ($ millions)
Exhibit 112: BMS: YoY revenue and growth rate of Orencia (ROW) 2012-2014 ($ millions)
Exhibit 113: Orencia sales for RA in major markets 2014
Exhibit 114: BMS: SWOT analysis
Exhibit 115: RA products by revenue 2014
Exhibit 116: F. Hoffmann-La Roche: YoY growth and revenue generated from product sales of MabThera/Rituxan 2011-2014 ($ billions)
Exhibit 117: MabThera/Rituxan geographic segmentation by revenue 2014
Exhibit 118: F.Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2012-2014 ($ millions)
Exhibit 119: Actemra/RoActemra geographic segmentation by revenue 2014
Exhibit 120: F. Hoffmann-La Roche: SWOT analysis
Exhibit 121: Johnson & Johnson: Segmentation of key drugs 2014
Exhibit 122: Johnson & Johnson: YoY growth rate and revenue of Remicade 2012-2014 ($ billions)
Exhibit 123: Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2012-2014 ($ billions)
Exhibit 124: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2012-2014 ($ billions)
Exhibit 125: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria 2012-2014 ($ millions)
Exhibit 126: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (in US) 2012-2014 ($ millions)
Exhibit 127: Johnson & Johnson: YoY growth rate and revenue of Simponi/Simponi Aria (ROW) 2012-2014 ($ millions)
Exhibit 128: Johnson & Johnson: SWOT analysis
Exhibit 129: Pfizer: Rhematoid drugs product segmentation by revenue 2014
Exhibit 130: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2012-2014 ($ billions)
Exhibit 131: Pfizer: YoY revenue and growth rate of Celebrex 2012-2014 ($ billions)
Exhibit 132: Pfizer: YoY revenue and growth rate of Xeljanz 2012-2014 ($ billions)
Exhibit 133: Pfizer: SWOT analysis
【レポート販売概要】
■ タイトル：関節リウマチ治療薬の世界市場：DMARD、NSAID、コルチコステロイド、鎮痛薬■ 英文：Global Rhematoid Arthritis Drugs Market 2016-2020
■ 発行日：2016年2月17日
■ 調査会社：Technavio
■ 商品コード：IRTNTR8751
■ 調査対象地域：グローバル
- 洋上風力発電の世界市場2015-2019About Offshore Wind Power Offshore wind power is the generation of electricity from wind by constructing wind farms in water bodies. It is estimated to be one of the cheapest and cleanest forms of electricity generation. Offshore wind turbines are larger in size and have greater wind speed compared with onshore wind turbines. Offshore wind power offers various advantages compared with onshore wind …
- 骨接合装置の世界市場分析：タイプ別（内部 – ネジ･プレート、ワイヤー･ピン、髄内ロッド･釘、脊柱固定装置; 外部骨折固定、骨延長）、材料別（分解性･非分解性）、セグメント予測、2013-2024The osteosynthesis devices market size is expected to reach a value of USD 9.9 billion by 2024, according to a new report by Grand View Research, Inc. The worldwide prevalence of conditions like osteoporosis and osteomalacia, coupled with heavily occurring road traffic injuries/accidents and sporting injuries support the demand for osteosynthesis devices worldwide. Osteoporosis, a disease resultin …
- クロマトグラフィー用試薬の世界市場：HPLC溶剤、GC溶剤、バッファー、シリル化試薬、アシル化試薬、イオン対試薬Chromatography technique helps separating and analyzing mixtures of chemicals in different application areas such as life sciences; food & beverage testing; environmental testing; forensics; and industries such as cosmetics, chemicals, oil, and petroleum, among others. The type of chromatography technique used depends on the sample to be analyzed or compounds to be separated. The global chromatogr …
- でんぷん誘導体の世界市場：でんぷん系甘味料（マルトデキストリン、シクロデキストリン、グルコースシロップ、加水分解物）、加工でんぷんAbout Starch Derivatives Starch derivatives are formed through a chemical reaction of raw starch, which contains hydroxyl groups and various functional groups. The derivatives formed have distinguished characteristics such as gelatinization, fluid viscosity, fluid paste stability, chemical resistance, and other applications. Starch derivatives have a wide range of applications in the Food and Beve …
- 世界のテスタ（Automated Test Equipment）市場動向（2014-2018）TechNavio’s analysts forecast the Global Automated Test Equipment market will grow at a CAGR of 2 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing demand for smart electronic devices. The Global Automated Test Equipment market has also been witnessing the increasing adoption of SoCs. However, the cyclic nature of the Semiconductor indus …
- 建設用化学品のアジア・MEA（中東・アフリカ）市場The Asia and MEA construction chemicals market was valued at $15,907.9 million in 2017 and it is expected to reach $27,740.7 million by 2025, growing at CAGR of 7.12% from 2018 to 2025. Construction chemicals are chemical formulations, which are majorly used with cement, concrete, or other materials to adhere them during construction activities. Construction chemicals are known to enhance the stre …
- 世界のワイヤレスオーディオデバイス市場2015The Global Wireless Audio Device Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Wireless Audio Device industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Wireless Audio Device market analysis is provided for the international markets including deve …
- 慣性計測装置（IMU）の世界市場予測（～2022年）：船舶、ナビゲーション、軍事、宇宙、商用Increased demand for accurate and reliable navigation is one of the significant factors driving the inertial measurement unit market. The inertial measurement unit market is projected to grow from an estimated USD 16.46 billion in 2017 to USD 21.74 billion by 2022, at a CAGR of 5.72% during the forecast period. This growth can be attributed to factors, such as high volume of production of consumer …
- フェノール樹脂の世界市場分析：製品別（ノボラック、レゾルツ）、用途別（木材接着剤、成形材料、断熱材、ラミネート、紙含浸･コーティング）、競争戦略、セグメント予測、2014-2025The global phenolic resins market is projected to reach USD 16.0 billion by 2025, according to a new report by Grand View Research, Inc. Technological advancements have fostered the development of unique heat shields with ablative phenolics for aerospace applications, leading to greater market share in recent years. Development of lignin and corn-based renewable feedstock have also presented new g …
- 世界の建設用シーラント市場2015The Global Construction Sealants Industry Report 2015 is a professional and in-depth study on the current state of the Construction Sealants industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Construction Sealants market analysis is provided for the international markets including development trends, …
- ドライアイ症候群：世界市場（医薬品市場予測及び分析～2022）PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022 Summary The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. That said, physicians suggest that the largest unmet need for DES tr …
- 包装チアシードの世界市場2017-2021ABSTRACTAbout Packaged Chia Seeds Chia seeds have a fine coat that can be easily digested. They have a neutral flavor and can be used to improve the nutrition and texture of baked goods, bread, confectionary, cereals, yogurts, and beverages. Chia seeds have a shelf life of over three years. They are oval-shaped seeds that encapsulate omega-3 oils and protect them from oxidization. Technavio’s anal …
- Tofogliflozin (Type 2 Diabetes)：市場予測と分析（～2022）Tofogliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Tofogliflozin (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 an …
- 肥料添加剤の世界市場：固化防止剤、脱塵剤、消泡剤、疎水剤、腐食抑制剤The fertilizer additives market is projected to grow at a CAGR of 2.6%, to reach a projected value of USD 2.91 Billion by 2021. The demand of fertilizer additives is completely dependent on the growth of the fertilizer industry. Furthermore, the shrinking arable land, adoption of new technology, and the increasing willingness of farmers to spend more for higher productivity are some important fact …
- TRx0237 (Alzheimer’s Disease)：市場予測と分析（～2022）TRx0237 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “TRx0237 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are …
